Results 41 to 50 of about 9,672 (236)

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]

, 2016
Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed, Kebriaeezadeh, Abbas, Keshavarz, Khosro, Lotfi, Farhad, Nikfar, Shekoufeh, Rezaei Hemami, Mohsen, Sanati, Ehsan   +6 more
core   +1 more source

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years

Medicina
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016.
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim   +8 more
doaj   +1 more source

Should they wait? Two children under 3 years old infected by HCV 1b successfully treated by ledipasvir/sofosbuvir: A report of two cases

Liver Research, 2023
Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Currently,
Mingna Li, Kuerbannisa Wulayin, Shutao Lin, Chao Wu, Lubiao Chen   +4 more
doaj   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, EarlyView.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Ledipasvir-Sofosbuvir for treating Chronic Hepatitis C: A NICE Single Technology Appraisal - An Evidence Review Group Perspective [PDF]

, 2016
The National Institute for Health and Care Excellence (NICE) invited Gilead, the company manufacturing ledipasvir-sofosbuvir (LDV/SOF), to submit evidence for the clinical effectiveness and cost-effectiveness of LDV/SOF for treating Chronic Hepatitis C.
Dickinson, K., Harrison, P., Ryder, S., Simpson, E., Stevens, J., Tappenden, P., Thokala, P.   +6 more
core   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced

Gut and Liver, 2017
Background/AimsChronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia.Methods : Patients (n=30) were enrolled between September 2015 and April 2016.
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim   +3 more
doaj   +1 more source

The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.

PLoS ONE, 2021
BackgroundSofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs.
Harriet Ho, Naveed Z Janjua, Kimberlyn M McGrail, Mark Harrison, BC Hepatitis Testers Cohort Team, Michael R Law   +5 more
doaj   +1 more source

Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelés nélkül 15–25 év alatt májzsugort, májelégtelenséget, májrákot okozhat.
Halász, Tünde, Horváth, Gábor, Hunyady, Béla, Makara, Mihály   +3 more
core   +1 more source